| abstract |
The present invention relates, in general, to HIV-1 antibodies including antibodies which bind to the surface of HIV-1 virus infected cells and/or mediate antibody-dependent cellular cytoxicity (ADCC)-, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention is directed to bispecific antibody molecules which comprise an arm targeting HIV-1 and a second arm targeting an effector cell. The invention further relates to compositions comprising such antibodies or antibody fragments, and their therapeutic use. |